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BACKGROUND: Cardiac hypertrophy is an independent risk factor for heart failure, a leading cause of morbidity and mortality 
globally. The calcineurin/NFAT (nuclear factor of activated T cells) pathway and the MAPK (mitogen-activated protein 
kinase)/Erk (extracellular signal-regulated kinase) pathway contribute to the pathogenesis of cardiac hypertrophy as 
an interdependent network of signaling cascades. How these pathways interact remains unclear and few direct targets 
responsible for the prohypertrophic role of NFAT have been described.
METHODS: By engineering cardiomyocyte-specific ETS2 (a member of the E26 transformation-specific sequence [ETS] 
domain family) knockout mice, we investigated the role of ETS2 in cardiac hypertrophy. Primary cardiomyocytes were used 
to evaluate ETS2 function in cell growth.
RESULTS: ETS2 is phosphorylated and activated by Erk1/2 on hypertrophic stimulation in both mouse (n=3) and human heart 
samples (n=8 to 19). Conditional deletion of ETS2 in mouse cardiomyocytes protects against pressure overload–induced cardiac 
hypertrophy (n=6 to 11). Silencing of ETS2 in the hearts of calcineurin transgenic mice significantly attenuates hypertrophic 
growth and contractile dysfunction (n=8). As a transcription factor, ETS2 is capable of binding to the promoters of hypertrophic 
marker genes, such as ANP, BNP, and Rcan1.4  (n=4). We report that ETS2 forms a complex with NFAT to stimulate transcriptional 
activity through increased NFAT binding to the promoters of at least 2 hypertrophy-stimulated genes: Rcan1.4 and microRNA-223 
(=n4 to 6). Suppression of microRNA-223 in cardiomyocytes inhibits calcineurin-mediated cardiac hypertrophy (n=6), revealing 
microRNA-223 as a novel prohypertrophic target of the calcineurin/NFAT and Erk1/2-ETS2 pathways.
CONCLUSIONS: Our findings point to a critical role for ETS2 in calcineurin/NFAT pathway-driven cardiac hypertrophy and unveil a 
previously unknown molecular connection between the Erk1/2 activation of ETS2 and expression of NFAT/ETS2 target genes.
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Heart failure is a leading cause of morbidity and mortality around the world, one that is increasing in incidence and prevalence.1 Whereas a num-
ber of efficacious therapies are available, including new 
ones emerging in recent years, the syndrome continues 
to have a major effect on individuals, society, and health 
care expenditures globally.
A major element of heart failure pathogenesis is 
hypertrophic growth of the myocardium. This growth 
response, left unchecked, culminates in heart failure.2–4 
Circulation is available at www.ahajournals.org/journal/circ
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Suppressing cardiac hypertrophy in patients with heart 
failure enhances contractile function and improves clini-
cal prognosis.5 Our understanding of mechanisms gov-
erning disease-associated hypertrophic growth of the 
myocardium is incomplete, and elucidating them holds 
the prospect of identifying new molecular targets with 
potential relevance as innovative therapeutic strategies.
Two of the major cellular signaling pathways driving 
cardiac hypertrophy are the calcineurin/NFAT (nuclear 
factor of activated T cells) pathway and the MAPK (mito-
gen-activated protein kinase)/Erk (extracellular signal-
regulated kinase) pathway.6 Sustained activation of 
either pathway results in a hypertrophic response.7 Sus-
tained activation of calcineurin in the heart is sufficient 
to induce pathologic cardiac hypertrophy that progresses 
rapidly to dilated hypertrophy and heart failure.7 In con-
trast, constitutive activation of Erk1/2 in the heart results 
in a milder hypertrophic response that does not appear to 
progress to failure.8 Whereas it is clear that Erk1/2 can 
be prohypertrophic, it has been suggested that it may 
also drive protective mechanisms during hypertrophic 
stress.9 Downstream targets of Erk1/2 that drive these 
events are unknown.
On activation by calcium, calcineurin binds to and 
dephosphorylates NFAT, resulting in the translocation of 
NFAT to the nucleus and activation of target genes.6,10 
Even though it is well-established that calcineurin/
NFAT signaling is crucial for cardiac hypertrophy, few 
prohypertrophic target genes of NFAT have been identi-
fied. This may be attributable, at least in part, to NFAT’s 
relatively weak DNA binding capability; often it coop-
erates with other transcription factors, such as MEF2 
(myocyte enhancer factor-2) and GATA4 (GATA bind-
ing protein 4), to form heterodimers with stronger DNA 
binding affinity.10,11
In T cells, NFAT interacts with ETS1 and ELF1 (E74-
like factor 1), 2 members of the E26 transformation-
specific sequence (ETS) domain family of transcription 
factors.12 In Th1 cells, ETS1 is required for the nuclear 
entry of NFAT and the recruitment of NFAT to the inter-
leukin-2 promoter.13 Like NFAT, ETS family members 
have been implicated in cardiac development,14–16 and 
ETS2 binding sites are overrepresented in the promot-
ers of genes upregulated in heart failure.17 A role for 
ETS2 in hypertrophic remodeling of the heart has not 
been described.
METHODS
The data, analytic methods, and study materials will be made 
available to other researchers for purposes of reproducing 
Clinical Perspective
What Is New?
• ETS2 (a member of the E26 transformation-spe-
cific sequence [ETS] domain family) is activated 
by Erk1/2 (extracellular signal-regulated kinase) in 
both hypertrophied murine hearts and in human 
dilated cardiomyopathy.
• ETS2 is required for both pressure overload- and 
calcineurin-induced cardiac hypertrophy, responses 
involving signaling cascades distinct from, but inter-
dependent with, Erk1/2 signaling.
• ETS2 synergizes with NFAT (nuclear factor of 
activated T cells) to transactivate Rcan1.4, an 
established downstream target of NFAT, and we 
identified microRNA-223 as a novel transcriptional 
target of NFAT/ETS2 in cardiomyocytes.
• In aggregate, these findings unveil a previously 
unrecognized molecular interaction between 2 
canonical hypertrophic signaling pathways: MAPK 
(mitogen-activated protein kinase)–driven hypertro-
phy and calcineurin-driven hypertrophy.
What Are the Clinical Implications?
• Because pathologic cardiac hypertrophy is an 
established risk factor for heart failure development, 
our unveiling of novel signaling mechanisms is of 
potential clinical relevance.
Nonstandard Abbreviations and Acronyms
αMHC α-myosin heavy chain
ANP atrial natriuretic peptide
BNP brain natriuretic peptide
βMHC β-myosin heavy chain
ChIP chromatin immunoprecipitation
CnA Calcineurin A
ELF1 E74-like factor 1
Erk extracellular signal-regulated kinase
ETS E26 transformation-specific sequence
GATA4 GATA binding protein 4
GFP green fluorescent protein
JNK c-Jun N-terminal kinase
KO knockout
MAPK mitogen-activated protein kinase
MCIP  modulatory calcineurin-interacting 
protein
MEF2 myocyte enhancer factor-2
MEK MAPK/Erk kinase
miRNA microRNA
MKP3 MAPK phosphatase 3
NFAT nuclear factor of activated T cells
NFATc1  nuclear factor of activated T cells, cyto-
plasmic 1
NRVM neonatal rat ventricular myocyte
siRNA small interfering RNA
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these results or replicating these procedures by reasonable 
request directed to the corresponding author.
Mice
Mice were housed and fed under standard laboratory con-
ditions with a 12 hours light/dark cycle from 6 am to 6 pm. 
Floxed ETS2 mice were a gift from Dr Michael C. Ostrowski 
(Department of Biochemistry and Molecular Biology, Medical 
University of South Carolina).18 To generate cardiomyocyte-
specific ETS2 knockout (KO) mice, floxed mice were bred 
with α-myosin heavy chain (αMHC)–Cre transgenic mice. 
ETS2 KO mice were crossed with calcineurin/MCIP (modu-
latory calcineurin-interacting protein) double transgenic ani-
mals19 to engineer ETS2 KO/calcineurin transgenic mice. 
All protocols were approved by the Institutional Animal Care 
and Use Committee of University of Texas Southwestern 
Medical Center.
Pressure-Overload Hypertrophy Model and 
Echocardiography
Male wild-type, αMHC-Cre, floxed, and ETS2 KO mice (FVB/N 
mice; 8 to 10 weeks of age) were subjected to severe thoracic 
aortic constriction (sTAC) as described previously.20,21 Mice 
were anesthetized by intraperitoneal injection of ketamine (100 
mg/kg) and xylazine (5 mg/kg). The left chest was opened at 
the second intercostal space to identify the thoracic aorta. The 
thoracic aorta was ligated with a 28-gauge needle, and then 
the needle was removed, leaving a region of stenosis. Sham-
operated mice underwent the same procedure without trans-
verse aortic banding and served as controls.
Echocardiography was performed on conscious, gently 
restrained mice using a Vevo 2100 system (VisualSonics) 
with a MS400C scanhead as described previously.22 M-mode 
recordings were obtained from a short axis view at the level of 
the papillary muscles. Left ventricular internal diameter (LVID) 
at both end-diastole (LVIDd) and end-systole (LVIDs) was mea-
sured at the time of the largest and smallest left ventricular 
areas, respectively. Fractional shortening was calculated as 
(LVIDd–LVIDs)/LVIDd ×100%. All parameters were measured 
at least 3 times; averages are presented.
Histologic Analysis
Mouse hearts were harvested and then fixed in 4% paraformal-
dehyde for 48 hours. Fixed hearts were embedded in paraffin and 
cut into 5-μm sections. Heart sections were stained with hema-
toxylin and eosin or wheat germ agglutinin to evaluate hyper-
trophic growth. Hematoxylin and eosin staining was performed 
using a standard method. For wheat germ agglutinin staining, 
deparaffinized and rehydrated heart sections were boiled in 
10 mmol/L citrate buffer (pH 6.0) for 12 minutes, followed by 
blocking in 1% bovine serum albumin with 5% goat serum for 
1 hour. Sections were then incubated with 10 μg/mL Alexa 
Fluor 594-conjugated wheat germ agglutinin (W11262; Thermo 
Fisher) for 1 hour at room temperature in the dark. After mount-
ing with the ProLong gold antifade reagent (P36935; Thermo 
Fisher), sections were imaged with a fluorescence microscope 
(Leica). Circular to oval left ventricular myocytes were chosen 
from >5 mice. At least 10 fields per mouse were evaluated. Cell 
size was quantified using Image-Pro Plus software.
Plasmid and Adenovirus Constructs
The ETS2 plasmid, encoding the full-length human ETS2 gene, 
was obtained from Addgene (28128). Truncated plasmids were 
constructed using Gibson assembly Master Mix (E2621; New 
England Biolabs). MicroRNA-223 (miR-223) reporter plas-
mid was obtained by subcloning the miR-223 promoter into 
pGL3-Basic vector. Luciferase assays were performed using 
the luciferase assay system (E1980; Promega). The Adeno-X 
Adenoviral System 3 kit (632267; Clontech) was used to 
generate an adenoviral vector expressing ETS2 (AdETS2) or 
mutated ETS2 (AdETS2 T72A and AdETS2 T72E).
Cell Culture and Treatments
Neonatal rat ventricular myocytes (NRVMs) were isolated 
from 1- to 2-day-old Sprague-Dawley rats using the Neonatal 
Cardiomyocyte Isolation kit (NC-6031; Cellutron). After 24 hours, 
medium was changed to 1% fetal bovine serum medium (Dulbecco 
Modified Eagle Medium/M199=3:1); the next day, it was changed 
to serum-free medium. NRVMs were then transfected with siR-
NAs (small interfering RNAs; Sigma) or infected with adenovirus. 
siRNA targeting ETS2 (SASI_Rn02_00225566 and SASI_
Rn02_00225568), MKP3 (SASI_Rn01_00074707 and SASI_
Rn01_00074714), and NFATc1 (number 1 sense siRNA sequence: 
5′-AGACAGACAUCGGGAGAAA-3′; antisense siRNA sequence: 
5′-UUUCUCCCGAUGUCUGUCU-3′; and number 2 sense 
siRNA sequence: 5′-CUACAUGGUUACUUGGAAA-3′; anti-
sense siRNA sequence: 5′-UUUCCAAGUAACCAUGUAG-3′) 
were used. Mission siRNA universal negative control number 1 
(SIC001; Sigma) was used as a negative control. Transfection was 
performed using siLentFect lipid reagent (1703361; Bio-Rad) in 
Opti-MEM medium (Invitrogen) for 6 hours. The medium was 
then changed to serum-free medium (Dulbecco Modified Eagle 
Medium/M199=3:1). After overnight serum starvation, cardio-
myocytes were treated with 50 μmol/L phenylephrine to induce 
hypertrophy. For signaling inhibition experiments, 10 μmol/L 
U0126 (19-147; Sigma) and 1 μmol/L PD0325901 (13034; 
Cayman) were used to inhibit MEK (MAPK/Erk)–Erk1/2 sig-
naling; 10 μmol/L SP600125 (S5567; Sigma) was used to 
inhibit JNK (c-Jun N-terminal kinase); 10 μmol/L SB203580 
(S8307; Sigma) was used to inhibit p38; 1 μmol/L cyclosporin A 
(SML1018; Sigma) was used to inhibit calcineurin.
Adult cardiomyocytes were isolated from wild-type, 
αMHC-Cre, floxed, and ETS2 KO mouse hearts as described 
previously.23 Briefly, hearts were perfused retrograde with 
Krebs-Ringer buffer (35 mmol/L NaCl, 4.75 mmol/L KCl, 1.19 
mmol/L KH2PO4, 16 mmol/L Na2HPO4, 134 mmol/L sucrose, 
25 mmol/L NaCO3, 10 mmol/L glucose, and 10 mmol/L 
HEPES; pH 7.4) and then digested by collagenase II (0.8 mg/
mL; Worthington). After removing atria and ventricles, cardio-
myocytes were collected by centrifugation.
HEK-293A cells were maintained in Dulbecco Modified 
Eagle Medium supplemented with 10% fetal bovine serum 
and 1% penicillin-streptomycin. Transfections were performed 
using Fugene 6 (E2691; Promega) according to the manufac-
turer’s instructions.
Immunofluorescence Analysis
NRVMs were rinsed twice with PBS and fixed with 4% para-
formaldehyde for 15 minutes. Subsequently, cardiomyocytes 
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were permeabilizated with 0.1% Triton X-100 in PBS for 
10 minutes and blocked with 3% bovine serum albumin for 
1 hour. Then, NRVMs were incubated with anti-α-actinin 
(A7732; Sigma) antibody overnight at 4°C. After 3 washes, 
cells were incubated with secondary antibody for 1 hour 
and sealed with ProLong gold antifade mountant with DAPI 
(4′,6-diamidino-2-phenylindole; P36935; Thermo Fisher) 
on slides. Cell circularity index was calculated as 4π*area/
perimeter.2
3H-Leucine Incorporation
L-[3,4,5-3H]-leucine (1 μmCi/mL; NET460A001MC; 
PerkinElmer) was added to the culture medium when NRVMs 
were treated with phenylephrine. After 48 hours, cardiomyo-
cytes were rinsed twice with PBS and incubated with 10% tri-
chloroacetic acid for 30 minutes at 4°C. After 2 washes with 
95% ethanol, NRVMs were lysed with 0.5 N NaOH overnight 
at 37°C with shaking. Equal volume of 0.5 N HCl was then 
added, and the total content was mixed with scintillation solu-
tion (882475; EcoLite; MP Biomedicals) before radioactivity 
measurement.
Western Blotting
Proteins were prepared with radioimmunoprecipitation assay 
buffer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1 
mmol/L EDTA, 0.25% sodium deoxycholate, 0.1% SDS) sup-
plemented with protease and phosphatase inhibitors (A32961; 
Thermo Fisher). Nuclear and cytoplasmic fractions were iso-
lated using a kit according to the manufacturer’s instructions 
(78835; Thermo Fisher). A total of 20 to 40 μg of proteins were 
separated using Criterion gels (Bio-Rad) and transferred to 
nitrocellulose membranes using the Trans-Blot Turbo Blotting 
System (Bio-Rad). The membranes were then blocked with 
5% nonfat milk or bovine serum albumin, followed by incuba-
tion with primary antibodies overnight at 4°C. After 3 washes, 
the membranes were incubated with secondary antibody 
and scanned with an Odyssey CLx Imaging system (LI-COR 
Biosciences). The following antibodies were used: anti-ETS2 
(sc-365666; Santa Cruz Biotechnology), anti-phospho-ETS2 
(44-1105G; Thermo Fisher), anti-GAPDH (10R-G109a; 
Fitzgerald), anti-RCAN1.4 (D6694; Sigma), anti-MKP3 (sc-
137246; Santa Cruz Biotechnology), anti-lamin A/C (2032; 
Cell Signaling), anti-NFATc1 (nuclear factor of activated T cells 
1; MA3-024; Thermo Fisher), anti-GFP (green fluorescent pro-
tein; A-11120; Invitrogen), anti-FLAG (7425; Sigma), anti-Myc 
(2276; Cell Signaling), anti-Erk1/2 (9107; Cell Signaling), and 
anti-phospho-Erk1/2 (9101; Cell Signaling).
Quantitative Real-Time PCR
Total RNA from heart tissues was extracted using an Aurum 
Fatty and Fibrous Tissue Kit (732-6870; Bio-Rad) and RNA 
from NRVMs was isolated using a Quick-RNA MicroPrep 
Kit (R1051; Zymo Research). Reverse transcription was 
performed using iScript Reverse Transcription Supermix 
(Bio-Rad) according to the manufacturer’s instructions. 
mRNA levels were determined by quantitative PCR using a 
LightCycler machine (Roche) and the iTaq Universal SYBR 
Green Supermix (Bio-Rad). All primer sequences are listed in 
Table I in the Data Supplement.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using 
the EZ-ChIP kit (17-10086; Millipore). Briefly, cells were cross-
linked with 1% formaldehyde for 10 minutes and harvested 
in SDS lysis buffer, followed by sonication to shear chroma-
tin. Cross-linked protein/DNA was immunoprecipitated with 
anti-ETS2 (365666X; Santa Cruz Biotechnology), anti-GFP 
(A-11120; Invitrogen), or control immunoglobulin G. Promoter 
binding was determined by quantitative PCR.
Coimmunoprecipitation
Coimmunoprecipitation was performed as described previ-
ously.24 Briefly, cells were lysed in immunoprecipitation buffer 
(50 mmol/L Tris-HCl, pH 7.5, 100 mmol/L NaCl, 2 mmol/L 
EDTA, 1% NP40) supplemented with protease and phospha-
tase inhibitors (A32961; Thermo Fisher). Proteins were incu-
bated with antibodies for 3 hours at 4ºC. After that, 30 μL of 
preequilibrated Dynabeads protein G (10003D; Bio-Rad) was 
added and incubated overnight at 4ºC. The beads were washed 
5 times with immunoprecipitation buffer before eluting with 2× 
Laemmli loading buffer and analyzed by Western blotting.
miRNA Inhibitor Transfection and miRNA 
Isolation
We studied miR-223-5p, which, for sake of simplicity, we 
refer to as miR-223 throughout the article. A total of 50 
nmol/L miR-223 inhibitor (MLTUD0340; Sigma) or the rel-
evant control (NCSTUD002; Sigma) was transfected into 
NRVMs. Low-molecular-weight RNA from heart tissues and 
NRVMs was isolated using the mirVana miRNA Isolation Kit 
(AM1560; Invitrogen) according to the manufacturer’s instruc-
tions. Reverse transcription was performed using the TaqMan 
MicroRNA Reverse Transcription Kit (4366596; Thermo 
Fisher). miR-223 levels were determined by quantitative PCR 
and normalized to U6.
Human Samples
Left ventricular tissues were harvested from patients with 
dilated cardiomyopathy. Control samples were obtained from 
healthy donors. Before cardiac tissue collection, informed con-
sent was obtained from the prospective donors. Our study con-
formed to the principles outlined in the Declaration of Helsinki 
and was approved by the ethics review committee of Tongji 
Hospital. Details regarding the patients are provided in Table II 
in the Data Supplement.
Statistics
All results are presented as mean±SEM of at least 3 inde-
pendent experiments. Normality of the distribution of data was 
assessed using the Shapiro-Wilk test, acknowledging the limi-
tation that small sample sizes prevent us from making a reli-
able assessment of normality. Homogeneity of variance was 
assessed by the F test (for 2 groups) or Brown-Forsythe test 
(for ≥3 groups). Data with normal distribution and equal vari-
ances were analyzed by unpaired 2-tailed Student t test (for 2 
groups) or 1-way ANOVA followed by Bonferroni post hoc test 
(for ≥3 groups). Otherwise, nonparametric statistical analyses 
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or the Kruskal-Wallis test followed by the Dunn post hoc test 
for multiple comparisons (for ≥3 groups). All statistical analyses 
were performed by GraphPad Prism 8 (GraphPad Software, Inc).
RESULTS
ETS2 Is Activated in Hypertrophic Hearts
To determine whether ETS2 participates in hypertrophic 
growth of the heart, adult wild-type mice were subjected 
to severe transverse aortic constriction (sTAC), a surgical 
model of pressure overload–induced cardiac hypertro-
phy.20 As expected, mice that underwent sTAC surgery 
displayed an initial hypertrophic response within 1 week 
that progressed to failure by 3 weeks. This response 
included increases in cardiac mass and cardiomyocyte 
size, hypertrophic marker gene expression, and progres-
sive declines in contractile function as compared with 
age-matched, sham-operated animals (Figure IA–IE in 
the Data Supplement). In both early and late stages of 
the response, ETS2 was activated in ventricular tissue, 
as evidenced by an increase of ETS2 phosphorylation at 
threonine 72 (Figure 1A). There was no change in ETS2 
protein or mRNA levels in whole tissue (Figure 1A and 
Figure IF in the Data Supplement). ETS2 phosphoryla-
tion was increased early in adult cardiomyocytes isolated 
from sTAC-subjected hearts, and high levels of p-ETS2 
persisted in the heart until 3 weeks (Figure IG in the 
Data Supplement). This was associated with an increase 
in ETS2 protein levels, but not mRNA levels (Figure IG 
and IH in the Data Supplement), suggesting an increase 
in protein stability. Cellular fractionation revealed an in-
crease in phosphorylated ETS2 in the nuclear fraction 
isolated from sTAC-treated hearts (Figure 1B and 1C). 
ETS2 steady-state protein levels were increased in both 
the cytoplasmic and nuclear fractions of adult cardiomy-
ocytes isolated from sTAC-treated hearts, but phosphor-
ylated ETS2 was increased only in the nucleus (Figure II 
in the Data Supplement).
Next, we tested whether these changes in ETS2 were 
mirrored in human heart failure. ETS2 abundance at both 
protein and mRNA levels was comparable in normal 
hearts and in hearts of patients with end-stage dilated 
cardiomyopathy (Figure 1D and Figure IJ and IK in the 
Data Supplement). However, ETS2 phosphorylation was 
increased 2-fold in dilated cardiomyopathy hearts (Fig-
ure 1D and Figure IJ in the Data Supplement). These 
results indicate that ETS2 is activated in the setting of 
hypertrophic growth of the myocardium and suggest that 
ETS2 may participate in its development.
ETS2 Deficiency Attenuates Cardiac 
Hypertrophy in Response to Pressure Overload
To test for a functional role of ETS2 in cardiac hyper-
trophy, we engineered cardiomyocyte-specific ETS2 KO 
mice by crossing ETS2-floxed (F/F) mice with αMHC-
Cre mice. ETS2 transcript levels were decreased >70% 
in the hearts of KO mice compared with either Cre mice 
or F/F mice (Figure IIA in the Data Supplement). This 
decrease was specific to cardiomyocytes (Figure IIB and 
IIC in the Data Supplement). Eight-week-old ETS2 KO 
mice did not manifest cardiac morphologic or functional 
changes, suggesting that loss of ETS2 in these animals 
did not affect heart development (Figure 2A–2E).
To test for potential effect of ETS2 on development 
and progression of cardiac hypertrophy, we again turned 
Figure 1. ETS2  is activated in hypertrophic hearts.
A, Western blot analyses and quantification showing ETS2 phosphorylation and protein levels in mouse hearts at 1 or 3 weeks after sham 
operation or severe thoracic aortic constriction (sTAC; n=3). B and C, Western blot analyses (B) and quantification (C) of ETS2 phosphorylation 
and protein levels in cytoplasmic and nuclear fractions extracted from sham-operated control hearts and sTAC-induced hypertrophied hearts 
(n=3). D, ETS2 phosphorylation is increased in hearts from patients with dilated cardiomyopathy (DCM; n=8 for normal controls, n=19 for DCM). 
**P<0.01; ***P<0.001. ETS2 indicates a member of the E26 transformation-specific sequence (ETS) domain family; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; ns, not significant; and sTAC, severe transverse aortic constriction.
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to the sTAC model. Animals underwent sham or sTAC 
surgery and cardiac phenotyping was carried out 3 weeks 
after surgery. As expected, control mice (F/F and Cre) 
developed significant increases in heart mass quantified 
as heart weight to body weight or heart weight to tibia 
length ratio as compared with sham controls (Figure 2A 
and Figure IID in the Data Supplement). However, this 
growth response was blunted in ETS2 KO hearts (Fig-
ure 2A and Figure IID in the Data Supplement). Function-
ally, sTAC elicited an increase in left ventricular diastolic 
and systolic dimensions in control mice, but resulted in 
no significant change in ETS2 KO mice (Figure IIE in the 
Data Supplement and Table III in the Data Supplement). 
Contractile function, quantified as % fractional shorten-
ing on echocardiography, was decreased in control ani-
mals after sTAC but remained preserved in ETS2 KO 
mice (Figure 2B and Table III in the Data Supplement).
Blunting of the hypertrophic response was also appar-
ent at the cellular level, where silencing of ETS2 attenuated 
increases in cardiomyocyte cross-sectional area in response 
to sTAC (Figure 2C–2E). Furthermore, sTAC-triggered 
induction of hypertrophic marker gene expression, such as 
ANP (atrial natriuretic peptide), BNP (brain natriuretic pep-
tide), βMHC (β-myosin heavy chain), and Rcan1.4, was dra-
matically inhibited in the hearts of ETS2 KO mice (Figure 2F 
and Figure IIF in the Data Supplement). Taken together, 
these results indicate that ETS2 is required for the normal 
cardiac remodeling response to elevated afterload.
ETS2 Is Required for Calcineurin-Induced 
Cardiac Hypertrophy
Involvement of ETS2 in regulating Rcan1.4 expression 
(Figure 2F and Figure IIF in the Data Supplement), a 
Figure 2. Cardiomyocyte-specific ETS2 (a member of the E26 transformation-specific sequence [ETS] domain family) knockout 
(KO) mice are protected from severe thoracic aortic constriction (sTAC)–induced cardiac hypertrophy.
A, The ratio of heart weight/tibia length (HW/TL) in α-myosin heavy chain–Cre (Cre), ETS2-floxed (F/F), and ETS2 knockout (KO) mice after 3 
weeks of sham or sTAC (n=6 to 11). B, ETS2 KO mice showed enhanced contractile function after sTAC. Left, M-mode echocardiography images; 
right, fractional shortening (n=6 to 11). C and D, Histologic analyses of heart sections from Cre, F/F, and KO mice subjected to sham or sTAC for 
3 weeks. Heart sections were stained with hematoxylin and eosin to analyze hypertrophic growth (C; scale bar, 2 mm) or stained with wheat germ 
agglutinin to demarcate cell boundaries (D; scale bar, 20 μm). E, Quantification of the relative cross-sectional area of the indicated groups (n=6 to 
8). F, mRNA levels of hypertrophic marker genes (ANP [atrial natriuretic peptide], BNP [brain natriuretic peptide], βMHC [β-myosin heavy chain], 
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well-known target of calcineurin/NFAT signaling,25 led 
us to consider whether ETS2 could play a role in cal-
cineurin-induced cardiac hypertrophy. To this end, we 
bred ETS2 KO mice with α-MHC-calcineurin transgen-
ic (CnA) mice.7,19 These CnA transgenic mice harbor a 
constitutively active mutant of the calcineurin catalytic 
subunit expressed specifically in cardiomyocytes.7 As 
expected, 4-week-old CnA transgenic mice manifested 
significant cardiac hypertrophy, with dramatically in-
creased heart weight and severe declines in contrac-
tile performance (Figure 3A–3E and Table IV in the 
Data Supplement). In contrast, hearts of ETS2 KO/CnA 
transgenic mice were much smaller than those of CnA 
mice at the same age (Figure 3A and Figure IIG in the 
Data Supplement). Silencing of ETS2 also diminished 
calcineurin-induced increases in left ventricular inter-
nal dimensions with marked improvement in contractile 
function (Figure 3B and Figure IIH in the Data Supple-
ment and Table IV in the Data Supplement). At the cellu-
lar level, calcineurin-driven increases in cardiomyocyte 
cross-sectional area and hypertrophic marker gene 
expression were blunted in ETS2 KO/CnA transgenic 
mice (Figure 3C–3F). Calcineurin-induced Rcan1.4 ex-
pression was repressed in the hearts of ETS2 KO/CnA 
transgenic mice (Figure 3F and 3G). Together, these 
results indicate that ETS2 is essential for calcineurin-
dependent cardiac hypertrophy.
These data suggest that ETS2 participates in both 
afterload-driven hypertrophic growth of the heart and 
that driven by calcineurin. To elucidate the role of ETS2 
in hypertrophic remodeling of the heart, we turned to 
NRVMs in culture. Similar to our observations with 
hypertrophic stress in vivo, phenylephrine increased car-
diomyocyte ETS2 phosphorylation (Figure 4A). ETS2 
steady-state protein levels, but not mRNA levels, were 
increased in NRVMs exposed to phenylephrine for 6 
hours or 24 hours (Figure 4A and Figure IIIA in the Data 
Supplement). Phenylephrine-induced increases in ETS2 
protein abundance were detected in both the cytoplasm 
and nucleus, but increased ETS2 phosphorylation was 
detected only in the nucleus (Figure 4B).
ETS2 Is Activated by Erk1/2 in Response to 
Phenylephrine
It has been reported that ETS2 is phosphorylated in mac-
rophages by MAPKs Erk1/2 and JNK.26–28 To test their 
involvement in cardiomyocytes, we exposed NRVMs to 
phenylephrine, an established hypertrophic growth cue 
acting via MAPKs,29–31 and used U0126, SP600125, 
and SB203580, specific inhibitors of MEK,30 JNK,32 and 
p38,33 respectively. Whereas JNK and p38 inhibition had 
no significant effect, inhibition of MEK-Erk1/2 signaling 
resulted in a dramatic decrease in ETS2 phosphoryla-
tion (Figure 4C and Figure IIIB in the Data Supplement). 
ETS2 protein levels were also decreased by Erk1/2 
inhibition, without change in ETS2 mRNA levels (Fig-
ure 4C and Figure IIIC in the Data Supplement). This re-
sult was corroborated independently with another MEK 
inhibitor,34 PD0325901 (Figure IIID and IIIE in the Data 
Supplement). These findings suggest that ETS2 is a tar-
get of Erk1/2 in cardiomyocytes, and ETS2 phosphoryla-
tion may be important for its protein stability.
Given our observation that ETS2 participates in calci-
neurin-induced cardiac hypertrophy, we examined ETS2 
phosphorylation levels in NRVMs exposed to adenovi-
rus expressing CnA. We observed an increase in ETS2 
phosphorylation in AdCnA-infected myocytes, but not in 
AdLacZ control myocytes (Figure IIIF and IIIH in the Data 
Supplement). Thus, ETS2 is phosphorylated (activated) 
in the settings of calcineurin-driven and Erk1/2-driven 
hypertrophic remodeling, lending additional credence to 
the notion of crosstalk between these pathways.
To test whether ETS2 is required for phenylephrine- 
or CnA-induced cardiomyocyte hypertrophy, or both, we 
silenced ETS2 in NRVMs by siRNA transfection using 
2 sequence-independent RNA interference constructs 
(Figure 4D) and exposed the cells to phenylephrine or 
infected them with CnA adenovirus. As expected, both 
phenylephrine-treated and AdCnA-infected NRVMs 
displayed a robust hypertrophic response, as indicated 
by increased cardiomyocyte size and protein synthesis 
(Figure 4E–4G and Figure IIII–IIIK in the Data Supple-
ment). These increases, triggered by either growth cue, 
were significantly suppressed by ETS2 knockdown (Fig-
ure 4E–4G and Figure IIII–IIIK in the Data Supplement). 
ETS2 silencing also inhibited expression of the hypertro-
phic marker genes ANP and BNP, although no change in 
βMHC expression was observed (Figure 4H and Figure 
IIIL in the Data Supplement). Expression of Rcan1.4 was 
significantly decreased after ETS2 knockdown, confirm-
ing our in vivo observations (Figure 4I and Figure IIIL–
IIIN in the Data Supplement).
To explore the role of Erk1/2 phosphorylation in this 
process, we used U0126, a specific inhibitor of MEK-
Erk1/2 signaling.30 As reported previously, inhibition of 
Erk1/2 decreased the phenylephrine-induced hypertro-
phic response in NRVMs (Figure IVA–IVC in the Data 
Supplement).30 Erk1/2 inhibition also reduced expres-
sion of the hypertrophic marker genes ANP, BNP, and 
Rcan1.4 to an extent similar to that occurring with ETS2 
gene silencing (Figure IVD–IVF in the Data Supplement). 
Unlike ETS2 inhibition, βMHC levels were also reduced 
with Erk1/2 inhibition, suggesting a broader role for 
Erk1/2 signaling under these conditions (Figure IVD in 
the Data Supplement).
ETS2 Activation by Erk1/2 Establishes an 
Inhibitory Feedback Loop Through MKP3
Findings reported thus far reveal that ETS2 is required 
for disease-related hypertrophic remodeling of the myo-
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Figure 3. ETS2 (a member of the E26 transformation-specific sequence [ETS] domain family) knockout (KO) suppresses 
calcineurin-induced cardiac hypertrophy.
A, Heart weight/tibia length (HW/TL) ratio of ETS2F/F and KO mice crossed with calcineurin transgenic mice (CnA; n=8). B, Echocardiographic 
analyses of cardiac function of ETS2F/F and KO mice crossed with calcineurin transgenic mice. Left, M-mode echocardiographic images; right, 
fractional shortening (n=8). C and D, Histologic analyses of heart sections from ETS2F/F and KO mice crossed with calcineurin transgenic mice. 
Heart sections were stained with hematoxylin and eosin (C; scale bar, 2 mm) or wheat germ agglutinin (D; scale bar, 20 μm). E, Quantification of 
the relative cross-sectional area of the indicated groups (n=8). F, mRNA levels of hypertrophic marker genes (n=8). G, Western blot analyses and 
quantification of Rcan1.4 protein levels in indicated groups (n=6). *P<0.05; **P<0.01; ***P<0.001. ANP indicates atrial natriuretic peptide; βMHC, 
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cardium culminating from 2 distinct signaling pathways. 
Next, we set out to determine whether ETS2 is sufficient 
to induce cardiac hypertrophy. To address this, we en-
gineered an adenovirus expressing ETS2 (Figure VA in 
the Data Supplement) and infected NRVMs. In control 
NRVMs, overexpressed ETS2 was located in the cyto-
plasm, but phenylephrine treatment resulted in its trans-
location to the nucleus (Figure VB in the Data Supple-
ment). ETS2 overexpression alone had no effect on cell 
size, protein synthesis, or hypertrophic marker gene 
expression (Figure VC–VH in the Data Supplement). 
Because phosphorylation of threonine 72 is crucial for 
ETS2 activity26,35 and is increased by hypertrophic stimuli 
(Figure 1A and Figure 4A), we engineered a phospho-
mimetic mutant by changing tyrosine 72 to a glutamine 
(T72E; Figure VA in the Data Supplement). The phos-
phomimetic was localized to the cytoplasm and did not 
induce hypertrophy or affect hypertrophic gene expres-
sion at baseline (Figure VB–VH in the Data Supplement).
We next evaluated whether ETS2 overexpression 
alters the hypertrophic response triggered by growth 
cues. We expressed in NRVMs wild-type, the T27E phos-
Figure 4. ETS2 (a member of the E26 transformation-specific sequence [ETS] domain family) knockdown attenuates 
phenylephrine-induced hypertrophy in vitro.
A, Representative Western blots and quantification showing ETS2 phosphorylation and protein levels in isolated neonatal rat ventricular myocytes 
(NRVMs) treated with 50 μmol/L phenylephrine (PE) for 6 or 24 hours (n=6). B, Western blot analyses and quantification of ETS2 phosphorylation 
and expression in cytoplasmic and nuclear fractions extracted from PE-treated NRVMs (n=4). C, ETS2 phosphorylation and protein levels in NRVMs 
treated with PE or MEK inhibitor U0126, or both, for 24 hours (n=6). D, ETS2 was silenced in NRVMs by small interfering RNA (siRNA) transfection. E, 
Representative immunofluorescence images of α-actinin staining in NRVMs transfected with siRNA control (siNC) or siRNA targeting ETS2 (siETS2) 
and then treated with PE for 48 hours. Scale bar, 20 μm. F, Quantification of relative cardiomyocyte surface area (n=50). G, ETS2 knockdown inhibits 
PE-induced protein synthesis in NRVMs (n=6). H, mRNA levels of ANP (atrial natriuretic peptide), BNP (brain natriuretic peptide), and βMHC (β-myosin 
heavy chain) in NRVMs transfected with siNC or siETS2 and then treated with PE for 24 hours (n=6). I, Rcan1.4 mRNA levels in NRVMs treated as in 
H (n=6). J, Chromatin immunoprecipitation (ChIP) analysis to detect ETS2 binding to the promoters of the indicated genes. ChIP was performed with 
an ETS2-specific antibody or immunoglobulin G control antibody in control NRVMs or NRVMs treated with PE or U0126, or both, for 6 hours. The 
occupancy of ETS2 at promoters is shown relative to background signals with immunoglobulin G control antibody (n=4). *P<0.05; **P<0.01; ***P<0.001. 
βMHC indicates β-myosin heavy chain; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; Ctrl, control; Cyto, cytoplasm; ETS2, a member of the 
E26 transformation-specific sequence (ETS) domain family; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ns, not significant; and nucl, nucleus.
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phomimetic, or the T27A phospho-null mutant ETS2 and 
induced hypertrophy with phenylephrine. At baseline, 
none of the constructs had an effect on hypertrophy (Fig-
ure VC–VE in the Data Supplement). On growth induc-
tion with phenylephrine, the T27A phospho-null mutant 
manifested a hypertrophic response similar to the GFP 
control (Figure VC–VE in the Data Supplement). Cells 
expressing either the wild-type or T27E construct did not 
manifest an exacerbated response, but rather showed an 
unexpected reduction of the hypertrophic response (Fig-
ure VC–VE in the Data Supplement). Even though phen-
ylephrine-induced increases in ANP and BNP mRNA 
levels were amplified by overexpression of wild-type ETS2 
or the T72E constitutively active mutant, cardiomyocyte 
size, protein synthesis, and Rcan1.4 expression were 
decreased under these conditions (Figure VC–VH in the 
Data Supplement). In aggregate, these results suggest 
that ETS2 overexpression inhibits hypertrophic growth in 
NRVMs in a manner that requires T27 phosphorylation.
To pursue this surprising result, we tested whether 
overexpression of ETS2 might be altering Erk1/2 signal-
ing through a negative feedback loop. Consistent with 
this, we found that both wild-type ETS2 and the T27E 
mutant, but not the T27A mutant, repressed Erk1/2 
phosphorylation in response to phenylephrine (Figure 
VIA in the Data Supplement).
In both 3T3 fibroblasts and cancer cells, ETS2 has 
been reported to bind to the promoter of MKP3 (MAPK 
phosphatase 3), an established mediator of Erk1/2 
dephosphorylation.36–38 We observed an increase in 
MKP3 expression in NRVMs treated with phenyleph-
rine (Figure VIB and VIC in the Data Supplement). ETS2 
was required for this, as ETS2 knockdown diminished 
MKP3 expression both at baseline and on phenylephrine 
treatment (Figure VID and VIE in the Data Supplement). 
Assessment of promoter binding by ChIP revealed that 
ETS2 occupies the MKP3 promoter in NRVMs (Figure 
VIF in the Data Supplement).
To test whether MKP3 has a role in ETS2-mediated 
Erk1/2 inhibition in cardiomyocytes, we first examined 
MKP3 expression in ETS2-overexpressing NRVMs. We 
found that whereas MKP3 message levels increase 
≈50% on exposure to phenylephrine, overexpression 
of wild-type ETS2 and the T27E mutant, but not T27A 
ETS2, further increased that response 2- and 3-fold, 
respectively, over untreated cells (Figure VIB and VIC 
in the Data Supplement). We next silenced MKP3 in 
ETS2-overexpressing NRVMs (Figure VIG in the Data 
Supplement) to determine whether ETS2 overexpres-
sion inhibits Erk1/2 via MKP3. We found that MKP3 
knockdown blocked the inhibitory effect of ETS2 on 
Erk1/2 signaling (Figure VIH in the Data Supplement). 
ETS2 overexpression promoted phenylephrine-induced 
hypertrophy in MKP3-silenced NRVMs (Figure VII–VIK 
in the Data Supplement). Together, these results indicate 
that whereas activation of ETS2 by Erk1/2 can drive 
cardiomyocyte hypertrophy, ETS2 also increases MKP3 
expression to inhibit Erk1/2 in a negative feedback loop.
Recognizing that ETS2 is a transcription factor, we next 
examined whether ETS2 binds to the promoter of hyper-
trophy-related genes in cardiomyocytes. ChIP analyses 
revealed that ETS2 binds to the promoters of ANP, BNP, 
and Rcan1.4, but not βMHC (Figure 4J). Phenylephrine 
increased the ability of the ETS2 antibody to immuno-
precipitate the promoters of ANP and BNP, whereas 
pulldown of the Rcan1.4 promoter was decreased in 
phenylephrine-treated NRVMs (Figure 4J). Erk1/2 inhi-
bition led to a significant decrease in ETS2 binding to all 
promoters, highlighting the importance of Erk1/2 phos-
phorylation of ETS2 in this pathway (Figure 4J).
ETS2 Synergizes With NFAT to Transactivate 
Rcan1.4
The observation that ETS2 binds to the Rcan1.4 promot-
er led us to investigate the relationship between ETS2 
and NFAT transcriptional activity more directly. We took 
advantage of a plasmid harboring the Rcan1.4 promoter 
linked to a luciferase coding region and performed re-
porter assays in HEK293 cells by adding plasmids ex-
pressing exogenous ETS2 and NFATc1. Transfection of 
ETS2 on its own increased the transcriptional activity of 
the Rcan1.4 promoter ≈5-fold (Figure 5A), whereas an 
ETS2 mutant lacking the DNA binding domain had no 
effect on Rcan1.4 promoter activity (Figure 5A). NFATc1 
alone transactivated the Rcan1.4 promoter ≈15-fold, 
whereas coexpression of ETS2 and NFATc1 resulted in 
a ≈30-fold increase in Rcan1.4 luciferase activity (Fig-
ure 5A). This synergy in activating the Rcan1.4 promoter 
was dependent on the DNA binding domain of ETS2 
(Figure 5A). We then tested another NFAT target gene, 
miR-23a. In contrast to the Rcan1.4 promoter, ETS2 had 
no effect on expression driven by the miR-23a promoter, 
and whereas NFATc1 activated this promoter, ETS2 did 
not alter this expression level (Figure VIIA in the Data 
Supplement). These data point to the existence of a spe-
cific subclass of NFAT/ETS2 target genes.
Promoter binding is an important regulatory mecha-
nism governing transcriptional activity. Therefore, ChIP 
was used to determine whether ETS2 influences the 
binding of NFATc1 to the Rcan1.4 promoter. Plasmid 
encoding full-length NFATc1 fused to GFP was trans-
fected into HEK293 cells and a GFP antibody was 
used for subsequent ChIP assay. As expected, both 
ETS2 and NFATc1 bound to the Rcan1.4 promoter (Fig-
ure 5B). Although NFATc1 did not affect ETS2 binding 
to the Rcan1.4 promoter, ETS2 increased the binding of 
NFATc1 to the Rcan1.4 promoter ≈4-fold (Figure 5B).
Synergy between ETS2 and NFATc1 led us to con-
sider whether there is an interaction between these 
2 molecules. Immunoprecipitation of a flag-tagged 














July 6, 2021 Circulation. 2021;144:34–51. DOI: 10.1161/CIRCULATIONAHA.120.05238444
Luo et al ETS2+NFAT Links Erk1/2 and Calcineurin
NFATc1 protein. Likewise, immunoprecipitation of the 
GFP-tagged NFATc1 resulted in pulldown of ETS2 pro-
tein (Figure 5C). To map the domain required for the 
interaction between ETS2 and NFATc1, truncated ETS2 
or NFATc1 was expressed in HEK293 cells. We found 
that ETS2 and NFATc1 bound to each other’s DNA bind-
ing domain (Figure 5D and 5E). Immunoprecipitation of 
endogenous ETS2 in NRVMs triggered significant pull-
down of NFATc1, and phenylephrine treatment resulted 
in greater pulldown of NFATc1 protein (Figure VIIB in 
the Data Supplement). Furthermore, the interaction 
between ETS2 and NFATc1 was detected exclusively 
in the nucleus in phenylephrine-treated NRVMs (Figure 
VIIC in the Data Supplement). These results indicate that 
ETS2 physically and functionally interacts with NFATc1 
to transactivate Rcan1.4 gene expression, suggesting 
cooperation between Erk1/2 and calcineurin in down-
stream targeting of a subset of hypertrophic genes.
MiR-223 Is a Downstream Target of ETS2 and 
NFAT in Cardiomyocytes
ETS proteins recognize sequences with a GGAA/T 
core motif, which is similar to NFAT binding sites 
Figure 5.  ETS2 (a member of the E26 transformation-specific sequence [ETS] domain family) cooperates with NFAT (nuclear 
factor of activated T cells) to regulate Rcan1.4 transcription.
A, Luciferase activity in HEK-293 cells transfected with an Rcan1.4 luciferase reporter plasmid, along with expression plasmids of ETS2, ETS2 
lacking DNA binding domain (ETS-△DBD), and NFATc1 (n=6). B, Chromatin immunoprecipitation (ChIP) analysis using an ETS2-specific antibody 
or a GFP antibody to detect ETS2 or NFATc1 binding to the Rcan1.4 promoter. HEK-293 cells were transfected with an ETS2 expression 
plasmid, a plasmid encoding full-length NFATc1 fused to green fluorescent protein (NFATc1-GFP), and an Rcan1.4 luciferase reporter plasmid. 
A total of 48 hours after transfection, cells were collected for ChIP analysis (n=4). C, ETS2 interacts with NFATc1. HEK-293 cells were 
transfected with expression plasmids of NFATc1-GFP and flag-tagged ETS2, then an ETS2-specific antibody and a GFP antibody were used 
for immunoprecipitation (IP) analysis, respectively. D, NFATc1 binds to ETS2 DBD. HEK-293 cells were transfected with expression plasmids of 
NFATc1-GFP and truncated ETS2, which has a myc tag. A total of 48 hours after transfection, cells were collected for IP analysis. E, ETS2 binds 
to NFATc1 DNA binding domain. HEK-293 cells were transfected with expression plasmids of flag-tagged ETS2 and truncated NFATc1, which 
has a myc tag, and then an IP assay was performed. **P<0.01; ***P<0.001. HLH indicates helix–loop–helix domain; IgG, immunoglobulin G; ns, 
not significant; SRD, serine-rich domain; and WB, Western blot.
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(GGAAA).39,40 Thus, we postulated that ETS2 and NFAT 
may share additional targets that are relevant to their 
roles in cardiomyocyte hypertrophy. To test this, we 
queried the Gene Transcription Regulation Database 
(http://gtrd20-06.biouml.org/) to identify genes har-
boring ETS2 or NFATc1 binding sites. Our search re-
vealed 4124 genes harboring ETS2 binding sites and 
15 124 genes harboring NFATc1 binding sites (Figure 
VIID and Spreadsheet I in the Data Supplement). Ap-
proximately 90% (3710) of the genes in the ETS2 
group were also found in the NFATc1 group, including 
Rcan1 (Spreadsheet I in the Data Supplement). This 
high degree of intersection suggests ETS2 and NFATc1 
share a large number of downstream target genes. To 
test this, we queried https://ccg.epfl.ch/ssa/findm.
php to find target genes that harbor ETS2 and NFATc1 
binding motifs in close proximity. The entire sequence 
range was set to –500 to approximately +100, and 759 
genes were found, including Rcan1 (Spreadsheet II in 
the Data Supplement).
Because miR-223 is a downstream target of ETS2 
in myeloid cells,41 and miR-223 is able to induce cardiac 
hypertrophy and heart failure,42 we tested whether ETS2 
regulates miR-223 expression in the heart. miR-223 
levels were significantly decreased in ETS2 KO mice on 
hypertrophic stimulation (Figure 6A and 6B). Consistent 
with this, knockdown of ETS2 in NRVMs also downregu-
lated miRNA-223 expression after phenylephrine treat-
ment (Figure 6C), as did inhibition of Erk1/2 (Figure VIIE 
in the Data Supplement). ChIP assays revealed that ETS2 
binds to the miR-223 promoter in cardiomyocytes and 
phenylephrine treatment increased ETS2 binding (Fig-
ure 6D). Silencing NFATc1 also dramatically decreased 
miR-223 levels in NRVMs (Figure 6E).
To further tease apart the relationship among ETS2, 
NFAT, and miR-223, luciferase reporter assays were 
performed. We constructed a reporter vector harboring 
the full-length miR-223 promoter and found that ETS2 
induced a small (≈2-fold) increase in reporter activity, 
whereas NFATc1 induced activity ≈10-fold over base-
line (Figure 6F). The combination of ETS2 and NFATc1 
resulted in >30-fold increase in miR-223 promoter activ-
ity (Figure 6F), a response that was abolished by deletion 
of the ETS2 DNA binding domain (Figure 6F).
To corroborate putative synergy between ETS2 and 
NFATc1, we performed an additional luciferase reporter 
assay using a vector harboring ≈700 bp of the miR-223 
promoter, thus removing the ETS2 binding site. ETS2 had 
no effect on the activity of this reporter, whereas NFATc1 
activated it (Figure VIIF in the Data Supplement). ETS2 
increased NFATc1-mediated induction of miR-223 
reporter activity (Figure VIIF in the Data Supplement), 
a response that was abolished by deletion of the ETS2 
DNA binding domain, which is also the binding site of 
NFATc1 (Figure VIIF in the Data Supplement). ChIP 
assays revealed that both ETS2 and NFATc1 bind to the 
miR-223 promoter (Figure 6G). Much like our findings 
with the Rcan1.4 promoter, NFATc1 did not influence 
ETS2 binding to the miR-223 promoter, but ETS2 dra-
matically increased NFATc1 binding to the miR-223 
promoter (Figure 6G). These results suggest ETS2 syn-
ergizes with NFAT to regulate expression of miR-223.
To further corroborate miR-223 as a downstream tar-
get of the calcineurin/NFAT/ETS2 pathway, we exam-
ined the effect of calcineurin on miR-223 levels. We 
found that calcineurin induced miR-223 expression in 
NRVMs, whereas cyclosporin A, an inhibitor of calcineu-
rin,7 blocked the induction of miR-223 by calcineurin, as 
did inhibition of Erk1/2 (Figure 6H). Calcineurin signifi-
cantly increased the luciferase activity driven by the miR-
223 promoter (Figure VIIG in the Data Supplement).
We next tested whether miR-223 is required for calci-
neurin-induced hypertrophy. We found that an miR-223 
antagomir attenuated calcineurin-mediated hypertrophy 
as measured by decreases in cell cross-sectional area, 
protein synthesis, and cell circularity index (Figure 6I 
and 6J and Figure VIIH–VIIK in the Data Supplement). 
Together, these results unveil miR-223 as a downstream 
target of both the Erk1/2 and calcineurin/NFAT path-
ways, with the 2 downstream effectors, ETS2 and NFAT, 
functioning in synergy to transactivate miR-223 to pro-
mote hypertrophy.
DISCUSSION
We set out to elucidate the role of ETS2 in hypertro-
phic remodeling of the heart. We report that ETS2 is ac-
tivated by Erk1/2 in both hypertrophied murine hearts 
and in human dilated cardiomyopathy. ETS2 is required 
for both pressure overload- and calcineurin-induced car-
diac hypertrophy, responses involving signaling cascades 
distinct from, but interdependent with, Erk1/2 signaling. 
We discovered that ETS2 synergizes with NFAT to trans-
activate Rcan1.4, an established downstream target of 
NFAT. We identified miR-223, an miRNA that has been 
suggested previously to induce cardiac hypertrophy, as 
a novel transcriptional target of NFAT/ETS2 (Figure 7). 
In aggregate, these findings unveil a previously unrec-
ognized molecular interaction between 2 canonical hy-
pertrophic signaling pathways: MAPK-driven hypertrophy 
and calcineurin-driven hypertrophy.
ETS2
Several transcription factors, including GATA4, MEF2, 
NKX2.5, and NFAT, play critical roles in hypertrophic re-
modeling of the myocardium.43 Responding to upstream 
signals, they regulate hypertrophic gene expression and 
induce cardiomyocyte growth. We identify the transcrip-
tion factor ETS2 as a previously unrecognized target 
of Erk1/2 in the setting of hypertrophic stress. On 
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Figure 6. MicroRNA (MiR)–223 is required for calcineurin-NFAT (nuclear factor of activated T cells)/ETS2 (a member of the E26 
transformation-specific sequence [ETS] domain family) pathway.
A, MiR-223 levels in the hearts of Cre, F/F, and knockout (KO) mice subjected to sham or severe transverse aortic constriction (sTAC) for 3 
weeks (n=6). B, MiR-223 levels in the hearts of ETS2F/F and KO mice crossed with calcineurin transgenic mice (n=8). C, MiR-223 levels in 
neonatal rat ventricular myocytes (NRVMs) transfected with small interfering RNA (siRNA) control (siNC) or siRNA targeting ETS2 (siETS2) and 
then treated with phenylephrine (PE) for 24 hours (n=6). D, Chromatin immunoprecipitation (ChIP) analysis using an ETS2-specific antibody to 
detect ETS2 binding to miR-223 promoter in control NRVMs or NRVMs treated with PE for 6 hours (n=4). (Continued )
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hypertrophy-related genes, activating their transcription. 
Silencing of ETS2 in the heart attenuates pressure 
overload–induced hypertrophic growth and significantly 
improves cardiac function.
ETS2, a member of the ETS-domain family, is expressed 
in many tissues, including the heart, throughout embryonic 
and neonatal development, extending into adulthood.44 
ETS2 plays an important role in regulating cell growth, 
differentiation, cell death, and tissue development.44 Simi-
lar to some other cardiac transcription factors, ETS2 is 
essential for proper myocardial development in Ciona 
intestinalis and chick embryos.15,16 By contrast, ETS2 KO 
mice develop and grow normally with no detectable abnor-
malities in cardiac function and morphology under physi-
ologic conditions, suggesting that ETS2 is not required for 
normal mouse postnatal cardiac development.
To test for a role of ETS2 in disease-related stress, 
we used a model of severe pressure overload (sTAC20). 
We chose this strategy, as opposed to standard trans-
verse aortic constriction, because FVB mice tend to be 
less susceptible to afterload stress as compared with 
C57BL/6 mice. In these experiments, control mice 
developed cardiac hypertrophy by 3 weeks but not 
contractile dysfunction. ETS2 deficiency, however, sig-
nificantly attenuated sTAC-induced cardiac remodeling; 
ETS2 KO mice manifested smaller hearts and cardio-
myocytes, enhanced contractile function, and decreased 
expression of hypertrophic marker genes compared with 
control mice exposed to sTAC.
Erk1/2 in Cardiac Hypertrophy
The role of Erk1/2 in the development of cardiac hyper-
trophy is controversial. Whereas in vitro NRVM models 
point to a role for Erk1/2,45 work in animals has yielded 
conflicting results.46 Cardiomyocyte-restricted transgenic 
expression of MKP3 decreases Erk1/2 autophosphory-
lation with no observable effect on heart mass or car-
diomyocyte cross-sectional areas after transverse aortic 
constriction, but decreased contractile function, sug-
gesting a protective role for Erk1/2.46 Subsequent work, 
however, suggested that a different autophosphorylation 
site on Erk1/2 contributed to hypertrophic signaling.47 
Whereas both studies examined gross changes in hyper-
trophy after transverse aortic constriction, neither exam-
ined the hypertrophic genes described here.
ETS2 is a known downstream target of Erk1/2.26 Our 
data demonstrate that ETS2 is phosphorylated in the 
setting of hypertrophic stress and that this phosphory-
lation requires Erk1/2 activity. In vitro, we demonstrate 
a requirement of ETS2 phosphorylation by Erk1/2 for 
development of hypertrophy and activation of ETS2 
downstream gene targets. In vivo, we show that ETS2 
plays an important role in stimulating cardiac hypertrophy 
and in the downstream activation of these hypertrophic 
response genes. Given that Erk1/2 may be targeting 
many factors, some pro- and some antihypertrophic, 
conflicting findings reported regarding Erk1/2-induced 
hypertrophy may not be surprising. ETS2 targets ANP, 
BNP, and Rcan1.4, all known to inhibit the hypertrophic 
response, while activating miR-233, which induces the 
hypertrophic response.48,49 In the case of ETS2, the over-
all effect is prohypertrophic. Clearly the Erk1/2 pathway 
and ETS2 seem to play especially prominent roles in 
phenylephrine-induced hypertrophy, but given the mul-
tiple stimuli activated in the heart exposed to pressure-
overload stress, it is not surprising that the protection 
observed in ETS2 KO mice is less robust. Because ETS2 
often works in concert with other transcription factors, it 
will be interesting to test whether specific interactions 
influence the spectrum of prohypertrophic versus protec-
tive downstream targets.
Crosstalk Between MAPK-Driven and 
Calcineurin-Driven Cardiac Hypertrophy
We show that ETS2 is also required for calcineurin- 
mediated cardiac hypertrophy. It is widely recognized that 
calcineurin/NFAT coupling contributes to pathologic car-
diac hypertrophy and progression to heart failure.7 Inhibi-
tion of the calcineurin/NFAT pathway has been shown 
to be an effective strategy for preventing hypertrophic 
growth.49–52 The ETS family of transcription factors share 
an evolutionarily conserved ETS domain that binds to 
purine-rich DNA sequences with a central GGAA/T 
core consensus, which is similar to NFAT binding sites 
(GGAAA).39,40 Two ETS family members, ETS1 and ELF1, 
exhibit binding sites adjacent to, or overlapping with, 
NFAT in several inducible lymphoid genes, such as in-
terleukin-2, interleukin-3, and granulocyte-macrophage 
colony-stimulating factor.53–57 Like NFAT, ETS2 transacti-
vates Rcan1.4, and overlapping binding sites of ETS2 and 
Figure 6 Continued. E, MiR-223 levels in NRVMs transfected with siNC or siRNA targeting NFATc1 (siNFATc1; n=6). F, Luciferase activity 
in HEK-293 cells transfected with a luciferase reporter plasmid harboring a full-length miR-223 promoter, along with expression plasmids of 
ETS2, ETS2 lacking DNA binding domain (ETS-△DBD), and NFATc1 (n=6). G, ChIP analysis using an ETS2-specific antibody or a GFP (green 
fluorescent protein) antibody to detect ETS2 or NFATc1 binding to the miR-223 promoter. HEK-293 cells were transfected with a miR-223 
luciferase reporter plasmid, along with expression plasmids of ETS2 and NFATc1-GFP. A total of 48 hours after transfection, cells were collected 
for ChIP analysis (n=4). H, MiR-223 levels in indicated NRVMs. NRVMs were infected with an adenovirus expressing constitutively activated 
calcineurin (AdCnA) or a control adenovirus (AdLacZ). Before harvest, calcineurin-overexpressing NRVMs were treated with cyclosporin A (CsA) 
or U0126 for 6 hours (n=6). I, Quantification of the relative cardiomyocyte cross-sectional area. NRVMs were transfected with antagomir control 
(antagomir-NC) or miR-223 antagomir and then infected with AdCnA for 48 hours (n=50). J, Protein synthesis in NRVMs treated as in (I; n=6). 
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NFAT are found within the Rcan1.4 promoter. Moreover, 
ETS2 is also required for calcineurin-induced cardiac hy-
pertrophy. We report that deletion of ETS2 in the heart of 
calcineurin transgenic mice dramatically attenuated car-
diac dysfunction and hypertrophic growth. Our findings 
further demonstrate that ETS proteins share targets with 
NFAT and in some cases they work cooperatively.
Because of weak DNA binding capability, NFAT often 
forms heterodimers with other transcription factors 
to direct gene transcription. We show that ETS2 binds 
directly to the Rcan1.4 promoter and cooperates with 
NFAT to transactivate Rcan1.4 expression. This effect is 
specific for only some NFAT target genes, as ETS2 had 
no effect on the induction of transcription by NFAT on 
miR-23a. Likewise, NFAT has been suggested to bind 
to GATA4 or AP-1 (activator protein-1) to activate the 
βMHC promoter58 and ETS2 does not appear to bind to 
or activate the βMHC promoter. These data point to a 
subset of targets specific for ETS2/NFAT signaling.
ETS2 has been reported to bind to the miR-223 pro-
moter to regulate its expression in myeloid cells.41 In car-
diomyocytes, miR-223 has been shown to be a positive 
regulator of cardiac hypertrophy.42 miR-223 transgenic 
mice develop cardiac hypertrophy and heart failure spon-
taneously, whereas cardiomyocyte silencing of miR-223 
protects against pathologic hypertrophic growth.42 Our 
report shows that miR-223 is a downstream target of 
ETS2/NFAT in cardiomyocytes. Knockdown of NFAT in 
NRVMs significantly decreased miR-223 levels. There 
are several NFAT binding sites within the miR-223 pro-
moter, and NFAT binds to the miR-223 promoter. We 
show that ETS2 synergizes with NFAT to transactivate 
miR-223 expression. We further show that calcineurin 
induces the transcriptional activation of miR-223, and 
miR-223 is essential for calcineurin-induced cardiac 
hypertrophy. In aggregate, these findings point to miR-
223 as a prohypertrophic target of the Erk1/2-ETS2/
calcineurin/NFAT pathway.
Negative Feedback Signaling
Our data also uncovered a negative feedback loop in-
volving ETS2. ETS2 overexpression prevented phen-
ylephrine-induced hypertrophic growth in NRVMs, an 
event stemming from ETS2-dependent inhibition of 
Erk1/2 signaling, which is critical for cell growth. We 
go on to demonstrate that ETS2 upregulates MKP3 
to inhibit Erk1/2 phosphorylation in NRVMs. MKP3 is 
Figure 7. Schematic illustrating signaling pathways regulated by ETS2 (a member of the E26 transformation-specific sequence 
[ETS] domain family) in cardiac hypertrophy.
Hypertrophic stress activates calcineurin and Erk1/2 Erk (extracellular signal-regulated kinase), which, in turn, activate nuclear factor of activated 
T cells (NFAT) and ETS2, respectively. ETS2 not only binds to the promoters of Rcan1.4 and microRNA (MiR)–223 in cardiomyocytes, it also 
synergizes with NFAT to transactivate Rcan1.4 and miR-223, and thus promotes cardiac hypertrophy. On the other hand, ETS2 binds to the MKP3 
promoter to upregulate MKP3 expression in response to hypertrophic stress, thereby inhibiting Erk1/2 signaling. ANP indicates atrial natriuretic 
peptide; BNP, brain natriuretic peptide; Erk, extracellular signal-regulated kinase; ETS2, a member of the E26 transformation-specific sequence 
(ETS) domain family; MKP3, MAPK phosphatase 3; and NFAT, nuclear factor of activated T cells.
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a MAPK phosphatase, a molecule that functions as a 
negative regulator of MAPK signaling. MKP3 specifi-
cally binds to Erk1/2 to inhibit Erk1/2 phosphoryla-
tion.59 Meanwhile, Erk1/2 directly phosphorylates ETS2 
to promote ETS2 binding to the MKP3 promoter in 3T3 
fibroblasts and cancer cells.37,38,60 Our study reveals that 
this feedback loop involving Erk1/2, ETS2, and MKP3 
also exists in cardiomyocytes and helps to explain dis-
crepancies previously reported in the literature. ETS2 
promotes phenylephrine-induced cardiac hypertrophy 
in MKP3-silenced NRVMs. Thus, ETS2 has dual roles 
in cardiac hypertrophy. On one hand, ETS2 synergizes 
with NFAT to activate miR-223 to induce hypertrophy. 
On the other hand, it inhibits Erk1/2 signaling to sup-
press hypertrophic remodeling. Therefore, our data 
suggest that under physiologic conditions ETS2 is pro-
hypertrophic, but when overexpressed it can tip the bal-
ance to suppress hypertrophy.
Functional crosstalk between calcineurin/NFAT and 
MEK-Erk1/2 signaling is widely recognized. Calcineurin 
is reported to activate Erk1/2 in the heart.61 Earlier work 
suggested that MEK-Erk1/2 signaling is essential for cal-
cineurin/NFAT-induced hypertrophy.62 Inhibiting Erk1/2 
by overexpressing MKP3 led to a significant decrease 
in NFAT DNA binding activity.62 Our data revealing that 
ETS2 stimulates NFAT binding to the Rcan1.4 promoter 
provides a molecular explanation for how Erk1/2 modu-
lates calcineurin/NFAT activity.
Summary and Perspective
Our findings demonstrate that ETS2 is required for hy-
pertrophic remodeling of the myocardium triggered by 
pressure overload, Erk1/2, and calcineurin. Our data 
support a model in which ETS2 is activated by Erk1/2 
and interacts with and recruits NFAT to specific gene 
promoters, including those of Rcan1.4 and miR-223. Our 
findings uncover miR-223 as a novel target of the calci-
neurin/NFAT/ETS2 pathway and provide new evidence 
for crosstalk between calcineurin/NFAT and Erk1/2 sig-
naling. Together, these findings reveal a previously unrec-
ognized molecular interaction between 2 canonical hy-
pertrophic signaling pathways: MAPK-driven hypertrophy 
and calcineurin-driven hypertrophy.
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